Immix Biopharma Inc Cash Flow-to-Debt Ratio
Immix Biopharma Inc cash flow-to-debt ratio. Immix Biopharma Inc (IMMX) has a Cash Flow-to-Debt Ratio of -1.15x as of June 2026, meaning its operating cash flow of $-11.74 Million could theoretically repay -1% of its total liabilities ($10.19 Million) in one year. See IMMX financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Immix Biopharma Inc (2019–2025)
Cash flow-to-debt ratio of Immix Biopharma Inc from 2019 to 2025. Historical debt coverage capacity for Immix Biopharma Inc across 7 annual periods. Check Immix Biopharma Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Immix Biopharma Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
Immix Biopharma Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Immix Biopharma Inc. For the full cash flow conversion analysis, see Immix Biopharma Inc (IMMX) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.17x | $-23.93 Million | $11.04 Million | ▼ -44.0% |
| 2024 | -1.51x | $-14.60 Million | $9.70 Million | ▲ +50.7% |
| 2023 | -3.06x | $-11.37 Million | $3.72 Million | ▲ +27.9% |
| 2022 | -4.24x | $-7.41 Million | $1.75 Million | ▲ +46.1% |
| 2021 | -7.87x | $-1.59 Million | $202.04K | ▼ -10144.0% |
| 2020 | -0.08x | $-404.69K | $5.27 Million | ▲ +55.4% |
| 2019 | -0.17x | $-790.03K | $4.59 Million | — |